表紙
市場調查報告書
商品編碼
808283

亞太地區的GLP-1(Glucagon-Like Peptide-1)受體激動劑市場 - 成長,趨勢,預測(2019年∼2024年)

Asia-Pacific Glucagon like Peptide - 1 (GLP - 1) Agonists Market - Growth, Trends, and Forecast (2019 - 2024)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

GLP-1(Glucagon-Like Peptide-1)受體激動劑,也稱為腸泌素類似藥物,以及反應食品攝取刺激胰島素分泌的荷爾蒙。

本報告提供亞太地區的GLP-1(Glucagon-Like Peptide-1)受體激動劑市場調查,市場概要,各醫藥品、各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場指標

  • 第一型糖尿病人口(實在數值、預測值)
  • 第二型糖尿病人口(實在數值、預測值)

第6章 市場區隔

  • 市場分析:各類醫藥品
    • Exenatide
    • Liraglutide
    • Lixisenatide
    • Dulaglutide
  • 市場分析:各地區
    • 亞太地區
      • 日本
      • 中國
      • 澳洲
      • 印度
      • 韓國
      • 馬來西亞
      • 印尼
      • 泰國
      • 菲律賓
      • 其他

第7章 競爭情形

  • 企業簡介
    • Novo Nordisk
    • Sanofi Aventis
    • Eli Lilly
  • 市場佔有率分析
    • Novo Nordisk
    • Sanofi Aventis
    • Eli Lilly
    • Astra Zeneca

第8章 市場機會及未來趨勢

目錄
Product Code: 62933

Market Overview

The GLP-1 drugs are also known as "incretin mimetics," a hormone that stimulates insulin secretion in response to meals.

GLP-1s are considered an adjunct to diet and exercise, to improve glycemic control in adults with type-2 diabetes mellitus.

Patients with type-2 diabetes have diminished insulin release in response to meals, and it is speculated that they may have defects in the release or action of their incretin hormones.

Diabetes prevalence has increased rapidly in recent decades. It is estimated that in 2007, more than 100 million Asians were living with diabetes. Concurrently with the rise in the diabetic population, obesity is also rising sharply because of economic development, increasing sedentary lifestyles, and nutrition transition.

Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia, i.e., China and Japan.

Scope of the Report

The Asia-Pacific region suffers from a high burden of diabetes, and its adverse health and economic consequences.

The disease is not only viewed as a serious threat, just from a public health perspective, but also from a development perspective.

With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in the low- and middle-income countries of the region.

It is one of the most common chronic diseases in China and India. The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.

Key Market Trends - Ever Increasing Prevalence of Diabetes

China tops the global list of countries for the total number of people with diabetes, followed by India. The number of people with diabetes in Japan has also increased significantly.

According to the IDF in 2013, it is estimated that Japan occupied the 10th position in the IDF list, with 7.2 million people with diabetes.

WHO projects that diabetes is likely to be the seventh leading cause of death by 2030. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years.

The growing prevalence of diabetes is the primary driver for the Asia-Pacific diabetes care market. Additionally, rising awareness regarding diabetes care, the ever-increasing prevalence of obesity, and technological advancements are further driving the market.

Japan is Dominating the GLP-1 Market in the Asia-Pacific Region

Japan holds the highest share in the Asia-Pacific GLP-1 agonist market, followed by China. GLP-1 receptor agonists have effective glucose-lowering efficacies and remarkable weight-loss effects, and are beneficial for diabetes treatment, especially for patients with overweight/obesity.

In Asia-Pacific, the revenue generated by the GLP-1 market was USD 384.04 million in 2017, and the market is expected to grow steadily during the forecast period, at a considerable rate of 15.93%. The growth of the market can be attributed to the fact that the type-2 diabetic population is on the rise and is expected to see further increase in the future, due to the lifestyle choices of individuals.

By brand, Victoza occupies the significant market share, at 62.07%, and it is expected to witness a growth rate of 11.49% during the forecast period. Trulicity held 26.24%, as of 2017.

Trulicity has a growth rate of 25.48% and is expected to reach almost the same overall market value as of Victoza, by 2024.

Competitive Landscape

The Asia-Pacific GLP-1 market is consolidated, with four major manufacturers holding a presence in the region.

Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Sajjala Bio, Hyderabad, India, recently announced developments in a liraglutide biosimilar, and the company is aiming to launch the product by the end of 2019.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET INDICATORS

  • 5.1 Type-1 Diabetes Population (2012-2024)
  • 5.2 Type-2 Diabetes Population (2012-2024)

6 MARKET SEGMENTATION

  • 6.1 By Drug
    • 6.1.1 Exenatide
      • 6.1.1.1 Byetta (Value and Volume, 2012-2024)
      • 6.1.1.2 Bydureon (Value and Volume, 2012-2024)
    • 6.1.2 Liraglutide
      • 6.1.2.1 Victoza (Value and Volume, 2012-2024)
    • 6.1.3 Lixisenatide
      • 6.1.3.1 Lyxumia (Value and Volume, 2012-2024)
    • 6.1.4 Dulaglutide
      • 6.1.4.1 Trulicity (Value and Volume, 2012-2024)
  • 6.2 Geography
    • 6.2.1 Asia-Pacific
      • 6.2.1.1 Japan (Value and Volume, 2012-2024)
      • 6.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.2 China (Value and Volume, 2012-2024)
      • 6.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.3 Australia (Value and Volume, 2012-2024)
      • 6.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.4 India (Value and Volume, 2012-2024)
      • 6.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.5 South Korea (Value and Volume, 2012-2024)
      • 6.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.6 Malaysia (Value and Volume, 2012-2024)
      • 6.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.7 Indonesia (Value and Volume, 2012-2024)
      • 6.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.8 Thailand (Value and Volume, 2012-2024)
      • 6.2.1.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.9 Philippines (Value and Volume, 2012-2024)
      • 6.2.1.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 6.2.1.10 Rest of Asia-Pacific (Value and Volume, 2012-2024)
      • 6.2.1.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 6.2.1.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk
    • 7.1.2 Sanofi Aventis
    • 7.1.3 Eli Lilly
    • 7.1.4 Astra Zeneca
  • 7.2 MARKET SHARE ANALYSIS
    • 7.2.1 Novo Nordisk
    • 7.2.2 Sanofi Aventis
    • 7.2.3 Eli Lilly
    • 7.2.4 Astra Zeneca

8 MARKET OPPORTUNITIES AND FUTURE TRENDS